SecBot SecBot
PRESS-RELEASE ·Filed Mar 11, 2026

BBIO

BridgeBio Pharma, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor upcoming FDA feedback and the full NDA submission in H1 2026 as key catalysts. Given the lack of current treatments and strong interim data, BBP-418 has high approval and commercial potential, supporting upside in BBIO shares. Watch for enrollment updates in planned pediatric and LGMD2M/2U trials as expansion signals.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$71.39
T+0 close · Mar 11, 2026 · via day close
Latest settled
−8.28%
T+60 · $65.48
Vs SPY
−19.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 11 $71.39entry
  2. T+1 · 8mo ago −4.78%α −3.29% · $67.98
  3. T+5 · 8mo ago −1.78%α +0.41% · $70.12
  4. T+20 · 7mo ago +5.79%α +5.26% · $75.52
  5. T+60 · 6mo ago −8.28%α −19.80% · $65.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio Pharma presented positive interim Phase 3 FORTIFY trial results for BBP-418, an oral therapy for LGMD2I/R9, showing rapid and sustained efficacy across key endpoints including ambulation and biomarker improvements, with a safety profile comparable to placebo. Based on these results, the company plans to submit an NDA to the FDA in the first half of 2026, with a potential U.S. launch in late 2026 or early 2027. If approved, BBP-418 would be the first therapy for LGMD2I/R9 and potentially the first for any limb-girdle muscular dystrophy (LGMD) subtype.

Key Facts

  • Positive interim Phase 3 FORTIFY trial results show BBP-418 improved ambulation (31-second advantage on 100MTT at 12 months vs. placebo) and reduced serum creatine kinase, with effects seen as early as 3 months.
  • BBP-418 demonstrated consistent benefit across all prespecified subgroups (genotype, age, FVC) and achieved normalization of CK in 38.3% of patients after 12 months.
  • Safety profile was favorable, with no treatment-related serious adverse events and no new safety signals.
  • BridgeBio plans to submit an NDA to the FDA in the first half of 2026, with a potential U.S. launch in late 2026/early 2027.
  • If approved, BBP-418 would be the first therapy for LGMD2I/R9 and potentially the first approved treatment for any LGMD subtype.

Financial Impact

High commercial potential due to first-mover status in a rare, underserved indication with significant unmet need; potential for premium pricing and rapid uptake in a defined patient population.

revenuemarketCapvaluation

Risk Factors

  • Interim data may not predict final trial outcomes; FDA may require additional data or reject the NDA.
  • Small patient population limits peak revenue potential despite high unmet need.
  • Recent insider selling ($132K in 30 days) could signal caution among executives.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3254081

Track record

38 reports on BBIO

Performance horizon

9 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 13 of 14 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (12h)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 11, 2026